title: Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.
abstract: OBJECTIVE
  To assess the effect of measles, mumps and rubella (MMR) vaccination on disease activity in children with juvenile idiopathic arthritis (JIA).
  
  
  METHODS
  A retrospective observational multicentre cohort study was performed in 314 patients with JIA, born between 1989 and 1996. Disease activity and medication use were compared during the period of 6 months before vaccination versus 6 months after vaccination. Disease activity was measured by joint counts, the Physician's global assessment scale and erythrocyte sedimentation rate. Next, we compared disease activity in patients vaccinated between 8 and 9 years of age with the activity in patients who had not been vaccinated at this time (who received MMR between the ages of 9 and 10 years).
  
  
  RESULTS
  No increase in disease activity or medication use was seen in the 6 months after MMR vaccination (n = 207), including in patients using methotrexate (n = 49). No overt measles infections were noted. When disease activity in vaccinated patients (n = 108) was compared with activity in those not yet vaccinated (n = 86), there were no significant differences.
  
  
  CONCLUSIONS
  The MMR booster vaccination does not seem to aggravate disease activity in JIA. This indicates that the most patients with JIA can be vaccinated safely with the MMR vaccine. A prospective study is recommended.
authors.affiliation: Department of Paediatric Immunology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Room KC 03-0630, PO Box 85090, 3508 AB Utrecht, The Netherlands.
authors.forename: Marloes W
authors.initials: MW
authors.lastname: Heijstek
authors.forename: Gecilmara C S
authors.initials: GC
authors.lastname: Pileggi
authors.forename: Evelien
authors.initials: E
authors.lastname: Zonneveld-Huijssoon
authors.forename: Wineke
authors.initials: W
authors.lastname: Armbrust
authors.forename: Esther P A H
authors.initials: EP
authors.lastname: Hoppenreijs
authors.forename: Cuno S P M
authors.initials: CS
authors.lastname: Uiterwaal
authors.forename: Wietse
authors.initials: W
authors.lastname: Kuis
authors.forename: Nico M
authors.initials: NM
authors.lastname: Wulffraat
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001171:Arthritis, Juvenile / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D022542:Measles-Mumps-Rubella Vaccine / Q000009:adverse effects*; D008727:Methotrexate / Q000008:administration & dosage; D012189:Retrospective Studies; D014611:Vaccination / Q000009:adverse effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D022542:Measles-Mumps-Rubella Vaccine; D008727:Methotrexate